Flumetasone
chemical compound
Flumetasone, also known as flumethasone, is a corticosteroid for topical use. It has anti-inflammatory, antipruritic, and vasoconstrictive properties, and it is approved for human and animal use for a variety of medical conditions.
It was patented in 1951 and approved for medical use in 1964.
Chemistry and mechanism of action
Flumetasone is classified as a moderately potent corticosteroid and a glucocorticoid receptor agonist. Like other corticosteroids, it functions as an immunosuppressant by decreasing function of the lymphatic system, reducing immunoglobulin and complement concentrations, lowering lymphocyte concentrations, and preventing antigen-antibody binding. Flumethasone is 420 times as potent as cortisone in an animal model for anti-inflammatory activity.
Society and culture
Names
Trade names include Locacorten, Locorten, and Orsalin. It is available in combination with clioquinol, under the brand name Locacorten-Vioform (in some countries Locorten-Vioform), for the treatment of otitis externa and otomycosis. It is usually formulated as the pivalic acid ester prodrug called flumetasone pivalate.
Veterinary uses
In April 2023, the US Food and Drug Administration approved the first generic version of flumethasone (Bimasone), for certain diseases that cause inflammation in horses, dogs, and cats.
“Flumetasone” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Flumetasone, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Flumetasone” is worth following because a concise public description often conceals a longer documentary argument. Here, Flumetasone, chemical and compound provides the most credible route into that argument.
The date and method of observation matter as much as the stated conclusion, especially where classification or consensus has changed. The source revision retrieved here is dated Dec 27, 2025. The linked authority identifier is Q4383636. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1951, 1964 and 2023.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Flumetasone”, its source revision and the description used here.
- Expand the search: follow Flumetasone primary sources, Flumetasone archive and Flumetasone research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Flumetasone”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Flumetasone” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.